BTIG Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

April 11, 2025 5:15 AM EDT Send to a Friend
BTIG analyst Julian Harrison reiterated a Buy rating and $82.00 price target on Protagonist Therapeutics (NASDAQ: PTGX)The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login